Trial
NCT01688336
FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
UNC Lineberger Comprehensive Cancer Center
Collaborators
—
Condition
Pancreatic Cancer
Intervention
FOLFIRINOX
Why stopped
Results unlikely to impact treatment patterns. Time to complete not justified.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-10-06